First PrEP In China: Gilead Faces Changing Market For Truvada
Generics Loom For Treatment Use
The China approval of Gilead’s Truvada in a new indication brings up a familiar question: how soon will domestic generics take over a new market with large potential amid a fast-changing environment?
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.